沈奇万调节OPN/CD44/PI3K通路以改善COPD中的呼吸道炎症:网络药理学,生物信息学和实验验证
Junhao Huang1, Xiaojie Zhou2, Yueling Xu1
1School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.
International immunopharmacology
|November 22, 2024
概括
沈奇万 (SQW) 通过抑制OPN/CD44/PI3K反循环,减少慢性阻塞性肺病 (COPD) 中的呼吸道炎症和氧化应激. 这种传统中医为COPD患者提供了一种新的治疗方法.
科学领域:
- 肺部医学 肺部医学
- 药理学 药理学是指药理学的学科.
- 生物标志物发现发现
背景情况:
- 慢性阻塞性肺病 (COPD) 由于未定义的致病性和有限的治疗选择,提出了重大挑战.
- 传统中国医学,神奇万 (SQW),对COPD有希望,但其分子机制需要阐明.
- 确定可靠的生物标志物和了解治疗途径对于推进COPD治疗至关重要.
研究的目的:
- 调查神奇万 (SQW) 改善慢性阻塞性肺病 (COPD) 呼吸道炎症和氧化应激的分子机制.
- 通过综合生物信息学和机器学习方法识别COPD的新生物标志物.
- 通过准OPN/CD44/PI3K通路来评估SQW的治疗潜力.
主要方法:
- 权重基因共同表达网络分析 (WGCWNA) 和机器学习被用来识别潜在的COPD生物标志物.
- 网络药理学预测了SQW目标和监管机制.
- 实验验证包括COPD小鼠模型,基于细胞的测试,免疫光学和西部斑点测试,以评估SQW对OPN/CD44/PI3K通路的影响.
主要成果:
- 骨质丁 (OPN) 被确定为一种潜在的COPD生物标志物,在患者中表达高.
- 在COPD模型中,SQW在改善肺功能和减少炎症和氧化应激方面表现出有效性.
- SQW抑制了涉及OPN,CD44和PI3K/Akt的正反循环,从而减少了气道炎症和氧化应激.
结论:
- 沈奇万 (SQW) 通过准OPN/CD44/PI3K正反循环,有效地缓解慢性阻塞性肺病 (COPD) 症状.
- 这项研究强调了OPN作为COPD的潜在生物标志物和治疗目标.
- SQW代表了COPD的有希望的治疗策略,通过抑制关键的炎症和氧化应激通路而起作用.
相关概念视频
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.7K
01:17Drugs Used in Lower Respiratory Disorders: Overview
352
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
352
01:26COPD: Management Using Bronchodilators and Corticosteroids
179
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
179
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
2.7K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.7K
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K
01:20COPD: Pathogenesis and Clinical Features
233
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
233